Raykov Rosty 4

What Happened
Raykov Rosty, a director of Fennec Pharmaceuticals (FENC), was reported as acquiring 5,208 shares on January 31, 2026. The shares were reported at $0.00 per share (total reported value $0) because they were released from restrictions tied to prior awards rather than bought for cash.

Key Details

• Transaction date: 2026-01-31; Form 4 filed 2026-02-02.
• Transaction type/code: A — Award/other acquisition (shares released from restriction).
• Shares acquired: 5,208; reported price: $0.00; reported total value: $0.
• Footnote: Shares were released from restrictions from awards originally granted 3/31/2023 and 5/16/2024.
• Shares owned after transaction: Not disclosed in this filing.
• Filing timeliness: Form 4 was filed on Feb 2, 2026; the filing does not indicate a late-reporting flag.

Context This transaction reflects the vesting/release of previously granted restricted shares rather than an open-market purchase or sale. Such releases are common as part of executive/director compensation and do not necessarily signal a change in the insider’s market view.